Indevus News (NASDAQ:IDEV)
| Latest Indevus Pharmaceuticals News Headlines | | Date | Time | Source | | | 10/07/2008 | 9:00AM | PRNUS | Beacon Equity Issues Technical Trade Alerts on Market Movers: DNDN, SPSN, SONS, CEGE, IDEV, ARDM
DALLAS, Oct. 7 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's Trade Alerts include: Dendreon Corp. (NASDAQ:DNDN), Spansion Inc. (NASDAQ:SPSN), Sonus... More...>> |
| 09/30/2008 | 8:00AM | PRNUS | Indevus Announces Initiation of Phase III Clinical Trial of Octreotide Implant for Acromegaly
LEXINGTON, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced the initiation of a Phase III clinical trial of the Company's novel octreotide implant for acromegaly. This trial is designed to test the efficacy, safety and tolerability of the octreotide implant in patients... More...>> |
| 09/26/2008 | 10:30AM | PRNUS | Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously announced promising data from... More...>> |
| 09/26/2008 | 9:00AM | PRNUS | Indevus and FDA Agree on Path Forward for NEBIDO(R)
Existing European Data Will Be Used for NDA Resubmission
LEXINGTON, Mass., Sept. 26 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) with regard to the additional data and risk management strategy that... More...>> |
| 09/16/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Scheduled to Present at 2008 UBS Global Life Sciences Conference
LEXINGTON, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that the Company will present at the 2008 UBS Global Life Sciences Conference in New York on September 22, 2008 at 2:30 p.m. eastern time. The presentation will be web cast live and may be accessed by visiting... More...>> |
| 08/26/2008 | 11:42AM | PRNUS | Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
Notes Secured by Royalties on U.S. Sales of SANCTURA(R) and SANCTURA XR(TM)
LEXINGTON, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced today that it has closed a private placement to institutional investors of $105.0 million of non-recourse notes (the "Notes"). The Notes... More...>> |
| 08/22/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
9,395 Women Enrolled in Trial Sponsored by Medical Research Council
LEXINGTON, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced today the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candidate vaginal microbicide for... More...>> |
| 08/13/2008 | 4:40PM | PRNUS | Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
LEXINGTON, Mass., Aug. 13 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals... More...>> |
| 08/05/2008 | 7:15AM | PRNUS | Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
LEXINGTON, Mass., Aug. 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced its consolidated results of operations for the third quarter ended June 30, 2008. The Company will host a conference call and webcast today beginning at 9:00 am eastern time (details follow below).
The Company... More...>> |
| 07/29/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Company to Conduct Conference Call and Webcast
LEXINGTON, Mass., July 29 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) will announce its third quarter 2008 financial results in a press release to be issued before market open on August 5, 2008. The Company will host a conference call and webcast... More...>> |
| 07/02/2008 | 10:00AM | PRNUS | BeaconEquity.com Issues TraderNotes on Active Stocks: WWAT, UCBH, PMTI, XMSR, IDEV, F, BUSE, HYGS
DALLAS, July 2 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's TraderNotes include: WorldWater & Solar Technologies Corp. (OTC:WWAT) (BULLETIN BOARD:... More...>> |
| 06/30/2008 | 10:21AM | PRNUS | Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Company Announces Revised Operating Plan to Respond to NEBIDO Delay
LEXINGTON, Mass., June 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NEBIDO(R) related to a New Drug Application... More...>> |
| 06/12/2008 | 8:00AM | PRNUS | Indevus Announces Management Changes
Company Begins Process to Restore Shareholder Value Following NEBIDO(R) Delay
LEXINGTON, Mass., June 12 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that Glenn L. Cooper, MD, its chairman and chief executive officer is postponing his previously-announced retirement to lead the... More...>> |
| 06/04/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
Company Expects FDA to Request Additional Safety Study Prior to Approval
LEXINGTON, Mass., June 4 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the NDA filing for NEBIDO(R), the Company expects... More...>> |
| 05/22/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR(TM) to Allergan, Inc.
LEXINGTON, Mass., May 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced the signing of a License Agreement with Allergan Inc., a Canadian affiliate of Allergan, Inc., based in Irvine, CA, granting Allergan the right to market SANCTURA XR(TM) (trospium chloride extended release... More...>> |
| 05/20/2008 | 4:15PM | PRNUS | Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
94 Percent of Men Maintained Normal Testosterone Levels Throughout Treatment
LEXINGTON, Mass., May 20 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that data on NEBIDO(R) (testosterone undecanoate), an investigational, long-acting intramuscular injection for the treatment of hypogonadism... More...>> |
| 05/15/2008 | 4:15PM | PRNUS | Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
LEXINGTON, Mass., May 15 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that the Company will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on May 19, 2008 at 4:55 p.m. local time (10:55 a.m. EDT) and at the 2008 UBS Global Generic and Specialty Pharmaceuticals... More...>> |
| 05/05/2008 | 4:00PM | PRNUS | Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Pube
LEXINGTON, Mass., May 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), the only once-yearly subcutaneous implant for the treatment of central precocious puberty or early onset puberty, at... More...>> |
| 04/30/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Announces Second Quarter Fiscal 2008 Financial Results
LEXINGTON, Mass., April 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced its consolidated results of operations for the second quarter of fiscal 2008, ended March 31, 2008. The Company will host a conference call and webcast today beginning at 9:00 am eastern time (details follow... More...>> |
| 04/23/2008 | 4:00PM | PRNUS | Indevus to Announce Second Quarter Fiscal 2008 Financial Results on Wednesday, April 30, 2008
Company to Conduct Conference Call and Webcast
LEXINGTON, Mass., April 23 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) will announce its second quarter fiscal 2008 financial results in a press release to be issued before market open on Wednesday, April 30, 2008. The Company will host a conference... More...>> |
|
|
|